Patents by Inventor Andrew B. Cubitt
Andrew B. Cubitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9637556Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: GrantFiled: October 11, 2013Date of Patent: May 2, 2017Assignee: AnaptysBio, Inc.Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
-
Patent number: 9260533Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: GrantFiled: February 14, 2014Date of Patent: February 16, 2016Assignee: AnaptysBio, Inc.Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
-
Publication number: 20140170705Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: ApplicationFiled: February 14, 2014Publication date: June 19, 2014Inventors: Peter M. BOWERS, Andrew B. CUBITT, Robert A. HORLICK
-
Publication number: 20140094392Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: ApplicationFiled: October 11, 2013Publication date: April 3, 2014Inventors: Peter M. BOWERS, Andrew B. CUBITT, Robert A. HORLICK
-
Patent number: 8685897Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: GrantFiled: May 17, 2011Date of Patent: April 1, 2014Assignee: Anaptysbio, Inc.Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
-
Patent number: 8603950Abstract: This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens.Type: GrantFiled: February 20, 2008Date of Patent: December 10, 2013Assignee: AnaptysBio, Inc.Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
-
Publication number: 20120028301Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.Type: ApplicationFiled: October 12, 2011Publication date: February 2, 2012Applicant: ANAPTYSBIO, INC.Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
-
Publication number: 20110287485Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).Type: ApplicationFiled: May 17, 2011Publication date: November 24, 2011Applicant: ANAPTYSBIO, INC.Inventors: PETER M. BOWERS, ANDREW B. CUBITT, ROBERT A. HORLICK
-
Publication number: 20110191873Abstract: This invention is directed towards methods of destabilizing proteins in living cells, and their use for the development of novel assays. In one embodiment, the invention comprises the use of non-cleavable multimerized ubiquitin fusion proteins to destabilize a target protein, such as a reporter moiety. In one aspect of this method the constructs also comprises a linker that operatively couples the reporter moiety to the multimerized ubiquitin fusion protein. In this embodiment, enzymatic modification of the linker results in a modulation of the coupling of the reporter protein to the multimerized ubiquitin domains resulting in a change in the stability of the reporter moiety. The level of the reporter moiety in the cell can then be used as a measure of the enzymatic activity in the cell. In another embodiment the invention provides for a generalized way of coordinately regulating the cellular concentration of a plurality of target proteins.Type: ApplicationFiled: November 2, 2010Publication date: August 4, 2011Inventors: Jeffrey Stack, Michael Whitney, Andrew B. Cubitt, Brian Pollok
-
Publication number: 20110183855Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.Type: ApplicationFiled: December 17, 2010Publication date: July 28, 2011Applicant: ANAPTYSBIO, INC.Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
-
Patent number: 7824850Abstract: This invention is directed towards methods of destabilizing proteins in living cells, and their use for the development of novel assays. In one embodiment, the invention comprises the use of non-cleavable multimerized ubiquitin fusion proteins to destabilize a target protein, such as a reporter moiety. In one aspect of this method the constructs also comprises a linker that operatively couples the reporter moiety to the multimerized ubiquitin fusion protein. In this embodiment, enzymatic modification of the linker results in a modulation of the coupling of the reporter protein to the multimerized ubiquitin domains resulting in a change in the stability of the reporter moiety. The level of the reporter moiety in the cell can then be used as a measure of the enzymatic activity in the cell. In another embodiment the invention provides for a generalized way of coordinately regulating the cellular concentration of a plurality of target proteins.Type: GrantFiled: June 22, 2007Date of Patent: November 2, 2010Assignee: Aurora Biosciences CorporationInventors: Jeffrey Stack, Michael Whitney, Andrew B. Cubitt, Brian Pollok
-
Patent number: 7560287Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: GrantFiled: August 23, 2004Date of Patent: July 14, 2009Assignees: The Regents of the University of California, State of Oregon acting by and through the State Board of Higher Education on behalf of the University of OregonInventors: Roger Y. Tsien, S. James Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormö
-
Publication number: 20090093024Abstract: This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens.Type: ApplicationFiled: February 20, 2008Publication date: April 9, 2009Applicant: AnaptysBio, Inc.Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
-
Publication number: 20090075378Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.Type: ApplicationFiled: February 20, 2008Publication date: March 19, 2009Applicant: AnaptysBio, Inc.Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
-
Publication number: 20080227129Abstract: This invention is directed towards methods of destabilizing proteins in living cells, and their use for the development of novel assays. In one embodiment, the invention comprises the use of non-cleavable multimerized ubiquitin fusion proteins to destabilize a target protein, such as a reporter moiety. In one aspect of this method the constructs also comprises a linker that operatively couples the reporter moiety to the multimerized ubiquitin fusion protein. In this embodiment, enzymatic modification of the linker results in a modulation of the coupling of the reporter protein to the multimerized ubiquitin domains resulting in a change in the stability of the reporter moiety. The level of the reporter moiety in the cell can then be used as a measure of the enzymatic activity in the cell. In another embodiment the invention provides for a generalized way of coordinately regulating the cellular concentration of a plurality of target proteins.Type: ApplicationFiled: June 22, 2007Publication date: September 18, 2008Inventors: Jeffrey Stack, Michael Whitney, Andrew B. Cubitt, Brian Pollok
-
Patent number: 7262005Abstract: This invention is directed towards methods of destabilizing proteins in living cells, and their use for the development of novel assays. In one embodiment, the invention comprises the use of non-cleavable multimerized ubiquitin fusion proteins to destabilize a target protein, such as a reporter moiety. In one aspect of this method the constructs also comprises a linker that operatively couples the reporter moiety to the multimerized ubiquitin fusion protein. In this embodiment, enzymatic modification of the linker results in a modulation of the coupling of the reporter protein to the multimerized ubiquitin domains resulting in a change in the stability of the reporter moiety. The level of the reporter moiety in the cell can then be used as a measure of the enzymatic activity in the cell. In another embodiment the invention provides for a generalized way of coordinately regulating the cellular concentration of a plurality of target proteins.Type: GrantFiled: February 4, 2000Date of Patent: August 28, 2007Assignee: Aurora Biosciences CorporationInventors: Jeffrey Stack, Michael Whitney, Andrew B. Cubitt, Brian Pollok
-
Patent number: 6780975Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: GrantFiled: February 5, 2002Date of Patent: August 24, 2004Assignees: The Regents of the University of California, Vertex Pharmaceuticals (San Diego) LLC, State of Oregon Acting by and through the State Board of Higher Education on behalf of the University of OregonInventors: Roger Y. Tsien, S. James Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormö
-
Publication number: 20030170767Abstract: The present invention includes a fluorescent compound that can detect an activity. such as an enzymatic activity, and exhibits quenching. The fluorescent compound can include a fluorescent protein, such as an Aequorea-related green fluorescent protein. The fluorescent compound can include a substrate site for an enzymatic activity such as a kinase activity, a phosphatase activity, a protease activity, and a glycosylase activity The fluorescent compound of the present invention can be used to detect such enzymatic activities in samples, such as biological samples, including cells. The present invention also includes nucleic acids that encode the fluorescent compounds of the present inventions, and cells that include such nucleic acids or fluorescent compounds.Type: ApplicationFiled: November 12, 2002Publication date: September 11, 2003Applicant: Aurora Biosciences CorporationInventor: Andrew B. Cubitt
-
Publication number: 20030036178Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use are provided.Type: ApplicationFiled: February 5, 2002Publication date: February 20, 2003Applicant: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, James S. Remington, Andrew B. Cubitt, Roger Heim, Mats F. Ormo
-
Patent number: 6495664Abstract: The present invention includes a fluorescent compound that can detect an activity, such as an enzymatic activity, and exhibits quenching. The fluorescent compound can include a fluorescent protein, such as an Aequorea-related green fluorescent protein. The fluorescent compound can include a substrate site for an enzymatic activity such as a kinase activity, a phosphatase activity, a protease activity, and a glycosylase activity. The fluorescent compound of the present invention can be used to detect such enzymatic activities in samples, such as biological samples, including cells. The present invention also includes nucleic acids that encode the fluorescent compounds of the present inventions, and cells that include such nucleic acids or fluorescent compounds.Type: GrantFiled: July 24, 1998Date of Patent: December 17, 2002Assignee: Aurora Biosciences CorporationInventor: Andrew B. Cubitt